~0.05 mg/mL in a 1:20 solution of DMF:PBS (pH 7.2); ~3 mg/mL in DMSO; ~5 mg/mL in DMF
Lestaurtinib is an indolocarbazole derivative and an inhibitor of several tyrosine kinases, including FLT3, JAK2, and TrkA.
It reportedly inhibits phosphorylation of STAT5 and other downstream effectors of JAK2 kinase in cells from patients with myeloproliferative disorders (MPDs). It prevents from activating mutations in the JAK2 tyrosine kinase. By this mechanism, it downregulates cell proliferation and has anti-cancer properties.
It has been demonstrated that lestaurtinib suppresses fms-like tyrosine kinase 3 (FLT3), therefore, it has been studied for treatment of acute myeloid leukemia (AML) by targeting FLT3.
• Used to study JAK/STAT signaling
• Therapeutic agent for patients with myeloproliferative disorders
• “A Randomized, Open-Label Study of Lestaurtinib (CEP-701), an Oral FLT3 Inhibitor, Administered in Sequence with Chemotherapy in Patients with Relapsed AML Harboring FLT3 Activating Mutations: Clinical Response Correlates with Successful FLT3 Inhibition.”
Not for human therapeutic use or for medicinal purposes. For research applications only.
Research or further manufacturing use only, not for food or drug use.